Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Trexquant Investment LP

Trexquant Investment LP lowered its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 85.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,527 shares of the company's stock after selling 136,734 shares during the quarter. Trexquant Investment LP's holdings in Nurix Therapeutics were worth $424,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after purchasing an additional 333,452 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Nurix Therapeutics by 3.0% during the fourth quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after purchasing an additional 104,500 shares during the period. Geode Capital Management LLC grew its position in Nurix Therapeutics by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 1,585,127 shares of the company's stock valued at $29,870,000 after purchasing an additional 137,087 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its holdings in Nurix Therapeutics by 42.7% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after buying an additional 235,971 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. increased its position in shares of Nurix Therapeutics by 42.8% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after acquiring an additional 236,620 shares in the last quarter.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.44 during trading on Friday, hitting $10.24. 1,322,027 shares of the company's stock traded hands, compared to its average volume of 887,503. The business has a 50-day simple moving average of $13.32 and a 200-day simple moving average of $18.85. The stock has a market capitalization of $780.66 million, a P/E ratio of -3.54 and a beta of 2.23. Nurix Therapeutics, Inc. has a 1 year low of $8.18 and a 1 year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period in the prior year, the company earned ($0.76) earnings per share. On average, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank of Canada increased their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. cut their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Stephens reiterated an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Finally, Wells Fargo & Company lowered their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.